Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers
This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB after weekly subQ MGB administration in up to 36 healthy volunteers at 1 site in Australia.
Healthy man or woman age 18 to 65 years, inclusive, at the Screening Visit [+16]
Evidence of clinically significant hematologic, renal, endocrine, pulmonary, car... [+10]